A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough to help patients remain on first-line trastuzumab deruxtecan, or T-DXd, plus pertuzumab.
The Useful Question Is Continuity, Not Gadgetry
This is not a smartwatch story in the breathless consumer-tech sense. It is a treatment-continuity story. For people with advanced or metastatic HER2-positive breast cancer, effective therapy only delivers its full value if toxicities can be recognized and managed before they force dose changes, interruptions, or discontinuation. Nobody should pretend an app cures that problem. But waiting until the next scheduled hospital visit can be a lousy system when symptoms evolve in between.
TOP-REAL plans to enroll roughly 300 patients across 60 centers in Spain, France, and Germany. Patients are already on study in Spain and France, while recruitment is open in Germany. The work is led by Spain-based Solti with Unicancer in France and West German Study Group in Germany. That cross-border design matters because digital care sounds simple in a slide deck and gets messy fast when it meets different hospitals, workflows, and healthcare systems.
Signals Are Only Valuable if Somebody Acts
The monitoring package combines electronic patient-reported outcomes, daily pulse oximetry, smartwatch-based continuous physiological data, and mobile platforms that vary by country and center: CANKADO or Resilience. Patients can report symptoms and physical changes outside the clinic, while the systems can generate recommendations or alerts. Sensible enough. The hard part, as ever, is whether an alert reaches a clinical team at the right moment and results in a timely assessment rather than becoming another flashing dashboard everyone learns to ignore.
- Daily oxygen-saturation measurements and periodic exercise tests will explore earlier signs that may warrant medical assessment.
- Interstitial lung disease, or pneumonitis, associated with T-DXd is among the toxicities under specific review.
- The oxygen and exercise approach is explicitly exploratory, which is the right label until evidence says more.
- The study will also examine quality of life, physical functioning, treatment continuity, biomarkers, and T-DXd rechallenge in selected patients.
Real-World Inclusion Is Where This Gets Interesting
TOP-REAL is not merely replaying a pivotal-trial script. It intends to include patient profiles that are often underrepresented in those trials, including selected patients with active brain metastases and people with an ECOG performance status of 2. That is important because routine practice does not politely filter itself into ideal study populations. If the treatment is to be used broadly, clinicians need evidence that speaks to the patients actually arriving in their offices.
The study will assess benefit and continuity through time to first subsequent anticancer therapy. It will also use the EORTC QLQ-C30 to track health-related quality of life and physical functioning. Tumor biopsies and blood samples are planned for biomarker analyses related to response and toxicity. Those pieces make TOP-REAL broader than a simple remote-monitoring feasibility exercise; it is trying to understand whether supportive care can fit alongside an effective regimen without losing sight of disease control.
Investors Should Resist the Easy Narrative
There is a business implication here, but it requires patience. AstraZeneca and Daiichi Sankyo support the study, and T-DXd plus pertuzumab sits at the center of the protocol. Better toxicity management could eventually strengthen confidence in using an effective regimen across a wider, more representative patient population. Yet that is a possibility, not a result. TOP-REAL has presented its design, not efficacy or safety outcomes. No one has supplied a readout date, alert thresholds, or proof that the digital signals will reduce interruptions.
That restraint is worth keeping. Digital monitoring has a habit of attracting grand promises, while oncology care demands evidence, staffing, and clinical judgment. Still, the study is asking a practical question with real human weight: can healthcare teams see deterioration sooner and preserve both quality of life and access to therapy? If TOP-REAL produces a credible answer across 60 centers and three countries, it could offer a more grounded path for bringing digital supportive care into everyday cancer treatment. That would be meaningful progress, no fireworks required.